Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Nature Communications
Vandekerkhove, Gillian G; Lavoie, Jean-Michel JM; Annala, Matti M; Murtha, Andrew J AJ; Sundahl, Nora N; Walz, Simon S; Sano, Takeshi T; Taavitsainen, Sinja S; Ritch, Elie E; Fazli, Ladan L; Hurtado-Coll, Antonio A; Wang, Gang G; Nykter, Matti M; Black, Peter C PC; Todenhöfer, Tilman T; Ost, Piet P; Gibb, Ewan A EA; Chi, Kim N KN; Eigl, Bernhard J BJ; Wyatt, Alexander W AW
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
British Journal Of Cancer
Gahr, S S; Stoehr, R R; Geissinger, E E; Ficker, J H JH; Brueckl, W M WM; Gschwendtner, A A; Gattenloehner, S S; Fuchs, F S FS; Schulz, C C; Rieker, R J RJ; Hartmann, A A; Ruemmele, P P; Dietmaier, W W
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Yeh, Paul P; Chen, Heidi H; Andrews, Jenny J; Naser, Riyad R; Pao, William W; Horn, Leora L
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
British Journal Of Cancer
Pallis, A G AG; Voutsina, A A; Kalikaki, Ar A; Souglakos, J J; Briasoulis, E E; Murray, S S; Koutsopoulos, A A; Tripaki, M M; Stathopoulos, E E; Mavroudis, D D; Georgoulias, V V